Avalyn Pharma Inc.

AVLN · Nasdaq · United States

Share price · AVLN

$27.69-11.17 (-28.74%) 3M

close as of 2026-11-18 · 24h delayed · vol 405K (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AVLN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 10 Nov 2026+5.7%

    Nothing announced by AVLN that day or the session before.

  2. 6 Nov 2026+9.3%

    Nothing announced by AVLN that day or the session before.

  3. 27 Oct 2026-4.8%

    Nothing announced by AVLN that day or the session before.

  4. 22 Oct 2026+8.5%

    Nothing announced by AVLN that day or the session before.

  5. 17 Jul 2026+10.2%

    Nothing announced by AVLN that day or the session before.

Share of unusual movement by asset

For each asset, the share of AVLN's own-move activity since 1 May 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Other company news (earnings, financing, releases naming no asset)—12%
Sessions with no dated event—88%

No dated announcements about its assets since 1 May 2026.

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
0Diseases
Showing 1 of 1 assets
Target & Modality
Phase 2
Mechanism not establishedSmall molecule
Indication not yet linked

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
June 2027 (1)
Pirfenidone (AP01)Phase 2Pulmonary Fibrosis, Progressive Pulmonary Fibrosis, Pulmonary Fibrosis Secondary to Systemic Sclerosis, Pulmonary Fibrosis …
Est. primary completion 2027-06 · NCT06329401 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Pirfenidone (AP01)Phase 2Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
Est. primary completion 2031-12-31 · NCT06951217 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (6)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3—$25M$145M+ $182M short-term inv.$30M-$26M operating cash flowreport ↗
View 5 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$25M$264M+ $88M short-term inv.$29M-$26M operating cash flowreport ↗
2026-Q1—$23M$92M+ $31M short-term inv.$27M-$30M operating cash flowreport ↗
2025-Q3—$22M$28M$24M-$17M operating cash flowreport ↗
2025-Q2—$18M$61M$20M-$21M operating cash flowreport ↗
2025-Q1—$15M$29M$18M-$19M operating cash flowreport ↗

Annual history (2 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY——$52M+ $86M short-term inv.—report ↗

Avalyn Pharma Inc. reported cash and equivalents of $52.32M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 1 more year
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY——$24M—report ↗

Insider transactions

Open-market activity, trailing 12 months: 4 purchases ($25.0M), 18 sales ($9.3M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-18Baranowski Lyn · director, Chief Executive OfficerOption exercise7,200$4.62$33KForm 4
2026-11-18Baranowski Lyn · director, Chief Executive OfficerOpen-market sale6,465$27.90$180KForm 4
2026-11-18Baranowski Lyn · director, Chief Executive OfficerOpen-market sale735$28.36$21KForm 4
2026-11-18Baranowski Lyn · director, Chief Executive OfficerOption exercise (derivative)7,200——Form 4
2026-11-17Carlson Douglas R · See RemarksOption exercise14,875$4.62$69KForm 4
2026-11-17Rhodes Melissa · Chief Operating OfficerOption exercise13,300$4.62$61KForm 4
2026-11-17Baranowski Lyn · director, Chief Executive OfficerOption exercise45,300$4.62$209KForm 4
2026-11-17Lazarus Howard · Chief Medical OfficerOption exercise13,300$4.62$61KForm 4